Table 1.
Application | Materials | In vitro | In vivo | Cite |
---|---|---|---|---|
Cartilage tissue engineering | GMA/SF | Human chondrocytes | Female athymic mice, rabbits | [59] |
Bone defect repair | n-HA-GO/SF | Rabbit bone marrow mesenchymal stem cells (BMSCs) | Male mice critical-sized bone defect models | [60] |
Ligament reconstruction | SF/HA-SF | Rat BMSCs | Rabbit models of ACLR | [61] |
Wound healing | CF@GO/SF | Human fibroblast (L929) cells | Rat models of wound | [62] |
Reconstitution of cardiac function | SF | Rat quiescent ventricular cardiomyocytes | Left ventricles of rats | [63] |
Vascular remolding | SF/GT | Mouse BMSCs | / | [64] |
Trachea reconstruction | SF/CVM | Human-induced pluripotent stem cells (hiPSCs) | Porcine tracheal defect models | [65] |
Artificial cornea engineering | PVA/SF/n-HA/GP | Human corneal fibroblasts (HCFs) | / | [66] |
Enamel regeneration | SF/HA | / | / | [67] |
Hepatic tissue engineering | SF | Stem cells from human exfoliated deciduous teeth (SHED) | / | [68] |
Bladder reconstruction | SF | Adipose-derived stem cells (ASCs) | Rat bladder augmentation models | [69] |
Nucleus pulposus replacement | SF/PU | / | Rabbits | [70] |
Nerve regeneration | Collagen/SF | Human umbilical cord mesenchymal stem cells (hUC-MSCs) | Rat models of SCI | [71] |
Tumor therapy | Biliverdin/SF | / | Mice tumor models | [49] |
Drug delivery | DEX/CSNPs/SF | L929 fibroblast cell line | / | [72] |
GMA: glycidyl methacrylate; n-HA: nanohydroxyapatite; GO: graphene oxide; ACLR: anterior cruciate ligament reconstruction; CF: ciprofloxacin; GT: gelatin-tyramine; CVM: collagen vitrigel membrane; GP: genipin; PU: polyurethane; SCI: spinal cord injury; DEX: dexamethasone; CSNPs: chitosan nanoparticles.